|
|
|
PRESS RELEASE
PrecisionLife and LifeArc Announce Strategic ALS Partnership as part of the Motor Neurone Disease Translational Challenge
-
LifeArc to select multiple novel targets identified by PrecisionLife with supporting patient stratification biomarkers for collaborative validation, development and partnering.
-
Partnership aims to develop and commercialise a portfolio of precision MND therapeutics supported by biomarkers for patients most likely to respond.
London and Oxford, UK, 15 May 2023 – Self funded, not-for-profit medical research organisation LifeArc and techbio company PrecisionLife announce a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for motor neurone disease (MND) - also known as amyotrophic lateral sclerosis (ALS), and Lou Gehrig's disease. The collaboration will accelerate pioneering findings by PrecisionLife working with the Motor Neurone Disease Association and leading clinicians at King’s College London and the University of Sheffield to analyse genotyped patient data and find novel genetic insights into the disease.
PrecisionLife’s studies resulted in the first mechanistic stratification of sporadic MND patients into clinically relevant subgroups and the identification of multiple novel druggable targets with supporting genetic evidence. Several of these have shown the potential to improve motor neurone survival in initial laboratory assays. PrecisionLife has also identified stratification biomarkers that can be used to recruit patients to clinical trials based on their mechanism of disease. This precision medicine approach promises to accelerate and derisk clinical development and, once medicines are approved, enable clinicians to prescribe the medication mostly likely to be effective for a specific patient.
The LifeArc MND Translational Challenge is part of a multi-million-pound programme to accelerate scientific innovation for people living with motor neurone disease. Its strategy will concentrate on fast tracking scientific discoveries into new clinical solutions that will transform the way MND is detected, treated and managed. By investing in collaborative projects LifeArc will deliver new tests, therapies and other medical technologies with the ultimate goal of making MND treatable by 2030.
LifeArc and PrecisionLife will work together to select and validate multiple novel targets and their accompanying patient stratification biomarkers. LifeArc researchers will lead and coordinate target validation and drug discovery projects. PrecisionLife will support the research undertaken at LifeArc with further detailed analyses to help select the most promising drug targets, find new targets as new datasets become available, identify opportunities that might exist for repurposing existing medicines, and advance the early-stage programmes towards development.
The partners will commercialise potential new treatments for patient benefit and revenue raised from commercialisation will continue to support LifeArc’s work to discover medical breakthroughs and improve human health.
Dr Brian Dickie, Director of Research Development, Motor Neurone Disease Association commented on the partnership: “It is really exciting to see the formation of such a potentially transformational partnership to support development of multiple new and bespoke therapeutic options for this devastating disease, where patients have such urgent unmet medical needs. Having worked with PrecisionLife and LifeArc I am convinced that in partnership these two organisations can make a significant step forward in finding new treatments.”
“MND has been a very important disease for PrecisionLife from our inception as our co-founder’s brother died from the disease as we set the company up” added Dr Steve Gardner, CEO, PrecisionLife. “Coupling a precision neuroscience approach to novel target discovery and validation with world-class translational development capabilities in MND is really exciting and holds real promise for accelerating the advances we all seek for partners and patients.”
“This is an exciting and important new partnership for us” said Dr Paul Wright, MND Translational Challenge Lead at LifeArc. “PrecisionLife’s expertise, resources and unique approach will be invaluable in helping us achieve our ambition of accelerating the development of new therapies for MND faster, and in doing so improve the treatments available for people living with MND and ultimately their survival prospects.”
ENDS
For further press information please contact:
Linda Todd at LifeArc
linda.todd@lifearc.org / 07753 962820
Noah Konig at PrecisionLife
noah@precisionlife.com / 07581 316270
Notes to Editors
About LifeArc
LifeArc is a self-funded, not-for-profit medical research organisation. We take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has resulted in five licensed medicines, including cancer drug pembrolizumab, and a diagnostic for antibiotic resistance.
Our teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. Our work is in translational science – bridging the gap between academic research and clinical development, providing funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives. LifeArc is committed to spending £1.3 billion by 2030 in areas of high unmet medical need. LifeArc is a company limited by guarantee and a registered charity.
Find out more about our work on www.lifearc.org or follow us on LinkedIn or Twitter.
About PrecisionLife
PrecisionLife is a pioneering techbio company extending precision medicine beyond oncology and rare diseases into complex chronic diseases that account for over 80% of healthcare spending.
Our unique approach generates the deepest disease insights and identifies mechanistic patient stratification biomarkers, informing drug discovery with novel targets matched to patient biology.
We derisk clinical development by identifying biomarkers associated with drug response to enable stratified clinical trials with a greater probability of success and develop precision diagnostic tools to prescribe effective treatments to the patients who will benefit from them.
With our insights into over 45 complex diseases, we've developed an extensive drug discovery pipeline of precision targeted therapies in areas of significant unmet need - creating a new age of better, more personalized therapy options.
Find out more at precisionlife.com | LinkedIn: @PrecisionLife | Twitter: @PrecisionLifeAI
About Motor Neurone Disease (MND)
MND is a progressive neurodegenerative disorder. Fewer than 50% of patients survive for more than two years after diagnosis.
The disease is inherited in only about 5-10% of cases. For the remaining 90-95% of patients, MND is classified as sporadic with no family history of the disease. Sporadic MND is not well understood, with no clearly associated risk factors and has no disease-modifying treatments.
For more information, visit www.mndassociation.org or download their MND factsheet.
